Lipid disorders involving derangements in serum cholesterol, triglycerides, or both are
commonly encountered in clinical practice and often have implications for cardiovascular …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has evolved as a pivotal enzyme in
lipid metabolism and a revolutionary therapeutic target for hypercholesterolemia and its …

Background Inclisiran inhibits hepatic synthesis of proprotein convertase subtilisin–kexin
type 9. Previous studies suggest that inclisiran might provide sustained reductions in low …

Lowering the levels of LDL cholesterol in the plasma has been shown to reduce the risk of
atherosclerotic cardiovascular disease (ASCVD). Several other lipoproteins, such as …

Coronary heart disease (CHD) is the leading cause of morbidity and mortality world-wide
and has been characterized as a chronic immunoinflammatory, fibroproliferative disease …

Elevated levels of low-density lipoprotein cholesterol (LDL-C) are associated with increased
risk of coronary heart disease and stroke. Guidelines for the management of dyslipidaemia …

606Recent clinical successes using therapeutic nucleic acids (TNAs) have accelerated the
transition of nucleic acid nanotechnology toward therapeutic applications. Significant …

The clinical benefit of lipid-lowering therapies is to reduce circulating levels of atherogenic
particles and to ameliorate the risk of atherosclerotic cardiovascular disease (ASCVD). The …

Due to a series of systemic and intracellular obstacles in nucleic acid (NA) therapy, including
fast degradation in blood, renal clearance, poor cellular uptake, and inefficient endosomal …

Background Inclisiran is a small interfering RNA agent to lower low-density lipoprotein
cholesterol. Objectives The purpose of this study was to provide reliable evidence to date on …